3-(1-dimethylaminoethyl)phenol,
NAP 226-90,
NAP-226-90,
NAP226-90,
139306-10-8,
(S)-3-(1-(dimethylamino)ethyl)phenol,
3-[(1S)-1-(DIMETHYLAMINO)ETHYL]PHENOL,
3-[(1S)-1-(Dimethylaminoethyl)]phenol,
(s)-3-[1-(dimethylamino)ethyl]phenol,
3-((S)-1-Dimethylamino-ethyl)-phenol,
UNII-1608PLR9ZO,
(S)-3-1(-Dimethylamino)ethylphenol,
(S)-3-1(- Dimethylamino)ethylphenol,
NAP 226-90,
NAP-226-90,
1608PLR9ZO,
(S)-3-(1-DIMETHYLAMINOETHYL)PHENOL,
Phenol, 3-[(1S)-1-(dimethylamino)ethyl]-,
3-((1S)-1-(Dimethylamino)ethyl)phenol,
Phenol, 3-((1S)-1-(dimethylamino)ethyl)-,
SAF,
A1-00312,
W-205531,
(S)-3-(1-N,N-dimethylaminoethyl) phenol,
1gqs,
AK-51758,
Phenol,3-[(1S)-1-(dimethylamino)ethyl]-,
PubChem9985,
Rivastigmine specified impurity A [EP],
rivastigmine intermediate 3,
rivastigmine intermediate 9,
(-)-3-((1S)-1-(Dimethylamino)ethyl)phenol,
AC1L9IQ3,
SCHEMBL47340,
RIVASTIGMINE METABOLITE,
Rivastigmine tartrate impurity, phenol impurity- [USP],
Jsp002349,
Rivastigmine hydrogen tartrate specified impurity A [EP],
CTK4C1743,
KS-00000ITG,
DTXSID60161005,
GQZXRLWUYONVCP-QMMMGPOBSA-N,
BH002,
ACT06150,
ZINC3591018,
ANW-45492,
CD-742,
FC0002,
FCH852934,
MFCD06656491,
AKOS015850730,
AC-3489,
AN-5378,
DB04556,
MB03878,
MG-0726,
RP22831,
RTR-005161,
(S)-3-[1-(Dimethylamino)ethyl] phenol,
ACM194930035,
AJ-45059,
BC222305,
3-[(1S)-1-(Dimethylamino)ethyl] phenol,
3-[(1S)-1-(Dimethylamino)ethyl]-phenol,
AB0012793,
AB1004573,
AX8018237,
DB-001145,
NAP226-90 (Rivastigmine EP Impurity A),
TR-005161,
AM20080948,
D4258,
FT-0649363,
FT-0658969,
ST24026583,
306D108,
3-[(1S)-1-(Dimethylamino)ethyl]phenol (Dimetol),
3-[(1s)1-(dimethylamino)ethyl]phenol(intermediateofrivastigmine),
(S)-3-(1-(dimethylamino)ethyl)phenol; 3-[(1S)-1-(DIMETHYLAMINO)ETHYL]PHENOL,
D0J9FT,
C10H15NO,
3-[1-(dimethylamino)ethyl]phenol,
CID445892,
CS-O-31056,
3-[1-[Di(methyl-d3)amino]ethyl]phenol,
(S)-3-[1-(Dimethylamino)ethyl]-phenol,
?3-[(1S)-1-(Dimethylaminoethyl)]phenol,
A3008,
EC 478-670-2,
(S)-3-[1-(Dimethylamino)ethyl]phenol, 99% - 1G 1g,
105601-04-5,